Replies to post #881 on Israel-Medical-Healthcare

[midastouch017]

Can-Fite receives milestone payment for its drug
The firm has an exclusive licensing agreement with Japan's Seikagaku Corporation.
Globes' correspondent 16 Oct 07 18:38
Can-Fite BioPharma Ltd. (TASE:CFBI) has taken a further step forward in its agreement with Japan's Seikagaku Corporation (SKK).
Can-Fite will receive a $500,000 milestone payment, following the final report on the results of its phase II FDA clinical trial drug CF101 for the treatment of rheumatoid arthritis in. The results were the same as those initially published following the trial, and they support the continued development of CF101.

Last year, Can-Fite signed an exclusive licensing agreement with SKK for the development and marketing of CF101 in Japan. Under the terms of the agreement, Can-Fite will receive a total of $19.5 million based on meeting specific milestones, and will also receive significant royalty payments from Japan sales of the drug.

So far, Can-Fite has received $5 million, and now will receive an additional $500,000.

Can-Fite and SKK are also collaborating on several non-clinical studies in the US aimed at supporting CF101 development in Japan, the US, and Europe. The two companies are sharing the costs associated with those studies.

Prof. Pnina Fishman, CEO of Can-Fite, stated today: "We are extremely satisfied with the cooperation with a fine partner such as SKK and from the benefit of being able to work jointly with them on various on-going projects. We have no doubt that this collaboration will considerably contribute to the overall progress of the CF101 development plan".

Published by Globes [online], Israel business news - www.globes.co.il - on October 16, 2007

[midastouch017]

Can-Fite liver cancer drug may regenerate liver
The company said it would be patenting the use of the drug for this purpose.

Gali Weinreb and Globes correspondent 21 Oct 07 16:19
Drug development company Can-Fite BioPharma Ltd. (TASE:CFBI) has disclosed that its CF102 drug for viral hepatitis was found in preclinical trials (on animals) to be effective in promoting liver tissue regeneration, following partial hepatectomy. "This procedure is usually performed in patients with primary of metastasic liver cancer. No drugs are currently available to speed the regeneration process," said the company in its announcement.
Can-Fite also announced that it would begin Phase I safety trials in the first quarter of 2008. The company said it believes the market for drugs that promote liver regeneration consists primarily of patients with hepatitis B and C. "Out of 130 million patients with hepatitis C and 350 million patients with hepatitis B, 100 million patients are at high risk of for developing liver failure or liver cancer, and may need drugs that speed up the regeneration of their infected liver during the course of the disease," it noted.

Can-Fite's share gained 4.5% in trading by mid-day on the Tel Aviv Stock Exchange (TASE) on Sunday, to give a market cap of NIS 190 million.

Published by Globes [online], Israel business news - www.globes.co.il - on October 21, 2007

[genisi]

Biotech co Can-Fite looks to Phase III trial

http://www.globes.co.il/serveen/globes/docview.asp?did=1000501282&fid=942

CEO Pnina Fishman: CF101 is unique for treating psoriasis, because it is given orally, and its safety and effectiveness profile are impressive.
Adi Ben-Israel29 Sep 09 11:51
Can-Fite BioPharma Ltd. (TASE:CFBI) today announced that it has begun preparations for the Phase III clinical trial of its flagship drug, CF101, for the treatment of psoriasis. Three weeks ago, the company announced that the Phase II trial of CF101 for this treatment was a success. If the Phase III trial is successful, the company can apply for marketing approval of the drug for this treatment.

In the Phase II trial, CF101 in 2 mg dosages was found effective in treating psoriasis. This dosage was found to be statistically significant most effective of the three dosages administered during the study.

Article continues after advertisements

Can-Fite will have to obtain approval of the US Food and Drug Administration (FDA) and other regulatory agencies to begin the Phase III trial. The company believes that these procedures will take several months, after which it will begin recruiting patients for the trial.

Can-Fite CEO Pnina Fishman said, "CF101 is unique for treating psoriasis, because it is given orally, and its safety and effectiveness profile are impressive."

Can-Fite's share rose 2.2% in morning trading to NIS 0.80, giving a market cap of NIS 167 million.